Asia Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size to Reach $3.7 Billion by 2035

Asia-Pacific dipeptidyl peptidase 4 (DPP-4) Inhibitors market size reached $2.4 billion in 2025 and is projected to expand to $3.7 billion by 2035, growing at a CAGR of 3.5% during the forecast period (2026–2035). Market growth is supported by rising diabetes prevalence, aging populations, and expanded access to oral antidiabetic therapies.

Browse the full report description of “Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market

Key Market Drivers

• Increasing prevalence of type 2 diabetes across urban and aging populations.
  • Growing preference for oral glucose-lowering therapies over injectable alternatives.
  • Expansion of public healthcare coverage for chronic disease medications.
  • Patent expirations enabling generic versions and wider affordability.
  • Rising screening rates and early diagnosis of metabolic disorders.

Regional Analysis

Asia-Pacific represents one of the largest patient pools for type 2 diabetes globally, driven by demographic shifts, urbanization, and lifestyle changes. Countries including China and India account for a substantial share of diagnosed and undiagnosed diabetes cases, creating sustained demand for glucose-lowering drugs such as DPP-4 inhibitors. In China, national health insurance inclusion of several antidiabetic medicines has improved treatment accessibility in both urban and rural settings. India continues to experience rising diabetes incidence linked to sedentary lifestyles and dietary transitions, prompting increased use of oral antidiabetic drug classes in primary care. Regional governments are also expanding chronic disease management programs, which support long-term pharmaceutical consumption. Japan and South Korea maintain high adoption of DPP-4 inhibitors due to physician familiarity and favorable safety profiles in elderly patients. Across Southeast Asia, improving healthcare infrastructure and insurance penetration are contributing to steady market expansion despite cost sensitivities.

Competitive Landscape

Key companies operating in the global Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors market include Merck & Co., Inc., Novartis AG, AstraZeneca plc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Lupin Limited. These companies manufacture branded and generic oral antidiabetic therapies and maintain distribution networks across major Asia-Pacific markets. Their activities include clinical research, regulatory approvals, lifecycle management, and expansion of combination therapies to address long-term diabetes treatment needs.

Recent Market Developments

• In January 2025 — Azurity Pharmaceuticals received FDA approval for Brynovin (liquid sitagliptin). This approval introduced the first oral liquid formulation of a DPP-4 inhibitor for adults with type 2 diabetes.
• In December 2024 — Trelagliptin, a once-weekly DPP-4 inhibitor, received approval from the Central Drugs Standard Control Organization (CDSCO) in India. This approval introduced a novel once-weekly oral DPP-4 inhibitor formulation aimed at improving glycemic control and treatment adherence in adults with type 2 diabetes mellitus.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By drug type
• Regions Covered-
  • Asia-Pacific
• Competitive Landscape - Merck & Co., Inc., Novartis AG, AstraZeneca plc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Lupin Limited.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment

By drug type

• Sitagliptin and vildagliptin
• Saxagliptin
• Linagliptin
• Gemigliptin
• Anagliptin
• Teneligliptin
• Others

Asia Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment by Region

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Countries
• Rest of Asia-Pacific

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market